Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy, such as dexamethasone, cisplatin, gemcitabine, and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal... Read More
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
08/03/2023
Locations: Rush-Presbyterian-St. Luke's Medical Centre, Chicago, Illinois +26 locations
Conditions: Lymphoma
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Completed
This research is being done because it is not yet known what dose of romidepsin in combination with gemcitabine, dexamethasone, and cisplatin (GDP) can be given safely to patients with peripheral T-cell lymphoma, nor what type and severity of side effects will result from the combination of these treatments. This research is also being done because it is not clear if the addition of the new drug romidepsin to treatment with GDP can offer better results and longer survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: Tom Baker Cancer Centre, Calgary, Alberta +5 locations
Conditions: Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Completed
The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to participants who are continuing to have clinical benefit and to continue collecting relevant safety data to monitor safety in participants with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for stem cell transplant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2023
Locations: Not set, Birmingham, Alabama +147 locations
Conditions: Multiple Myeloma
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Terminated
The purpose of this clinical phase I/II study was to investigate the safety and tolerability of satoreotide tetraxetan (177Lu-IPN01072, formerly known as 177Lu-OPS201) used for the treatment of patients with neuroendocrine tumors (NETs). The secondary objectives of this study were the assessment of biodistribution, dosimetry and preliminary efficacy of satoreotide tetraxetan.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: MD Anderson Cancer Center, Department of Nuclear Medicine, Houston, Texas +8 locations
Conditions: Neuroendocrine Tumors
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
Completed
The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out after 6 months of follow-up. The primary outcome is perce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Jules Stein Eye Institute, UCLA, Los Angeles, California +32 locations
Conditions: Uveitis, Macular Edema
Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining PSC 833 with chemotherapy may reduce resistance to the drug, and allow more tumor cells to be killed. It is not yet known whether combination chemotherapy plus PSC 833 is more effective than combination chemotherapy alone in treating patients with relapsed or refractory multiple myeloma. PURPOSE: Randomized phase II... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/14/2023
Locations: University of California San Diego Cancer Center, La Jolla, California +39 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Completed
The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of pomalidomide, bortezomib and low dose dexamethasone is compared to the combination of bortezomib and low dose dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2023
Locations: Southern Cancer Center, Mobile, Alabama +320 locations
Conditions: Multiple Myeloma
Comparing Local Anesthesia With and Without iPACK Block
Recruiting
Total knee arthroplasty is an effective surgical intervention for patients with chronic osteoarthritis commonly performed worldwide. Postoperative pain management has been a key focus in patient care for this procedure. Poorly controlled pain following total knee arthroplasty is associated with decreased ambulation, increased length of hospital stay, increased complications (particularly related to significant opioid use), and overall suboptimal patient recovery. Appropriate postoperative pain m... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/08/2023
Locations: University of Calgary/AB Hip and Knee Clinic, Calgary, Alberta
Conditions: Osteo Arthritis Knee, Analgesia, Pain, Postoperative
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Terminated
This phase I trial studies the side effects and best dose of pomalidomide and bortezomib when given together with dexamethasone in treating patients with amyloid light-chain amyloidosis or light chain deposition disease. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop abnormal cells from growing. Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth. Giving pomalidomide and bortezomib togethe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2023
Locations: Colorado Blood Cancer Institute, Denver, Colorado +4 locations
Conditions: Light Chain Deposition Disease, Primary Systemic Amyloidosis
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for childhood acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing different regimens of combination chemotherapy to see how well they work in treating children with acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
04/04/2023
Locations: Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama +122 locations
Conditions: Leukemia
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of chemotherapy is more effective for acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing four regimens of combination chemotherapy to see how well they work in treating children with newly diagnosed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/04/2023
Locations: Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama +122 locations
Conditions: Leukemia
Dexamethasone for Reduction of Post Thoracotomy Pain Syndrome
Recruiting
Post thoracotomy pain syndrome still affects 50% of patients after a thoracic surgery. Pathogenesis is unclear but there is growing evidence that neuro inflammation may play a significant role. Dexamethasone is a very potent anti-inflammatory drug. The hypothesis of this study is that dexamethasone, given pre operatively, would help reduce the incidence of post thoracotomy pain syndrome 3 months after surgery, by reducing the inflammatory response, in patients undergoing elective thoracic surger... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/17/2023
Locations: Maisonneuve-Rosemont Hospital, Montreal, Quebec
Conditions: Chronic Pain, Dexamethasone, Thoracic Surgery, Cytokines